Viewing records where tag name contains "investor" View All

Ansell launches VivaGel® condom in Canada

Apr 12th, 2017

Starpharma is pleased to announce the VivaGel® condom has been launched in Canada by Ansell under the LifeStyles® Dual Protect brand. 

Read More

VivaGel® BV phase 3 trials for prevention of BV completed

Mar 30th, 2017

Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced completion of its international, multicentre, phase 3 clinical studies evaluating VivaGel® BV for the prevention of recurrent bacterial vaginosis (rBV). Starpharma expects topline results of the trials to be available in the second quarter of 2017.

Read More

Starpharma VivaGel® BV gets FDA fast track

Jan 13th, 2017

The Australian reports that Bell Potter sees further upside for Starpharma, setting its share price target at $1.05, given the company had been granted Qualified Infectious Disease Product (QIDP) and fast track designation for VivaGel® BV by the US Food and Drug Administration.

 Go to the article (external link)

Read More

VivaGel® BV granted QIDP and Fast Track designation by US FDA

Jan 12th, 2017

Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation for VivaGel® BV by the US Food and Drug Administration (FDA).

Read More